Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.

Research square·2026
Same author

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Cancer·2026

Related Experiment Video

Updated: May 16, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes.

Marina N Sharifi1,2, Jamie M Sperger1,2, Amy K Taylor1,2

  • 1Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.

Cancer Discovery
|April 1, 2025
PubMed
Summary

Treatment resistance drives lethal prostate cancer. Researchers identified four distinct cancer cell lineages linked to patient outcomes in metastatic prostate cancer using a new isolation technique.

More Related Videos

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Related Experiment Videos

Last Updated: May 16, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Treatment resistance is a primary cause of mortality in metastatic prostate cancer.
  • Genomic alterations and cellular lineage plasticity contribute to treatment resistance.

Purpose of the Study:

  • To investigate the role of circulating tumor cell (CTC) phenotypes in metastatic prostate cancer prognosis.
  • To identify distinct CTC lineages associated with treatment resistance and patient outcomes.

Main Methods:

  • Developed and utilized a novel high-purity method for isolating circulating tumor cells (CTCs).
  • Performed transcriptional profiling of isolated CTCs to characterize lineage phenotypes.
  • Correlated identified CTC lineage phenotypes with patient prognosis in metastatic prostate cancer.

Main Results:

  • Identified four distinct CTC lineage phenotypes in patients with metastatic prostate cancer.
  • Demonstrated differential prognostic associations among these four lineage phenotypes.
  • Established a link between CTC lineage plasticity and treatment resistance in prostate cancer.

Conclusions:

  • Circulating tumor cell (CTC) lineage phenotypes are significant prognostic indicators in metastatic prostate cancer.
  • The novel CTC isolation and profiling approach provides insights into mechanisms of treatment resistance.
  • Understanding these lineage phenotypes may lead to improved therapeutic strategies for prostate cancer.